MGX logo.png
MeiraGTx Reports First Quarter 2024 Financial and Operational Results
May 09, 2024 08:00 ET | MeiraGTx
- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented in an oral session at the American Academy of Oral Medicine 2024 annual meeting (AAOM) April 17-20, 2024 -...
282529224901463569.jpg
Xunlei Limited Schedules 2024 Unaudited First Quarter Earnings Release on May 16, 2024
May 09, 2024 08:00 ET | Xunlei Limited
SHENZHEN, China, May 09, 2024 (GLOBE NEWSWIRE) -- Xunlei Limited (“Xunlei” or the “Company”) (NASDAQ: XNET), a leading technology company providing distributed cloud services in China, today...
Reviva Logo.png
Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting
May 09, 2024 08:00 ET | Reviva Pharmaceuticals
CUPERTINO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...
VERA_Thumbnail.jpg
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
May 09, 2024 08:00 ET | Vera Therapeutics
Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatmentTopline 96-week data from ORIGIN 2...
ACV Logo_Gradient.png
ACV to Participate in Upcoming Investor Conferences
May 09, 2024 08:00 ET | ACV
BUFFALO, N.Y., May 09, 2024 (GLOBE NEWSWIRE) -- ACV (Nasdaq: ACVA), a leading digital automotive marketplace and data services partner for dealers and commercial clients, announced today that...
DISC_Med_Stacked_Logo_one_color_Red (1).png
Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024 08:00 ET | Disc Medicine Inc
Presented top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), in April 2024On track to deliver additional analyses from BEACON and...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024 08:00 ET | Phathom Pharmaceuticals
Over 17,500 total prescriptions for VOQUEZNA® products have been dispensed, launch-to-date, a 361% increase since last quarterly report Net revenues of $1.9 million reported for the first full...
Corbus Logo.jpg
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
May 09, 2024 08:00 ET | Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of...
Annexon_Logo_RGB.png
Annexon Biosciences to Present at the Bank of America Health Care Conference
May 09, 2024 08:00 ET | Annexon Biosciences
BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with...
AKOYA Bio - Logo - Standard Centered.png
Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients
May 09, 2024 08:00 ET | Akoya Biosciences, Inc.
MARLBOROUGH, Mass. and FRANKFURT, Germany, May 09, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and NeraCare, a leading developer of laboratory...